Inbal Michailovici

Inbal Michailovici currently serves in Investment Management at Arkin Bio Ventures since November 2023, and is a Board Member at CatchMe Therapeutics from January 2023. Prior roles include Director of Business Development at FutuRx from February 2020 to January 2023, Biotech Analyst at Medison Pharma Ltd. from September 2017 to October 2019, and Business Development Analyst at BioLineRx from March 2015 to September 2017. Inbal also completed a postdoctoral fellowship at the Weizmann Institute of Science focusing on calcium and ERK signaling in muscle stem cells. Inbal holds a PhD in Developmental Biology from the Weizmann Institute and has experience in academic instruction as a Senior Lecturer in a Medical Science Course at Beer-sheva and the Negev College. Education includes an M.Sc. from Tel Aviv University and a B.Sc. from Ben Gurion University of the Negev, with a background in cancer therapy and cell biology research.